As part of efforts to expand its footprints in Nigeria and across African Continent, Micro Labs Limited (Micro Labs), India has acquired Swiss Pharma Nigeria Limited (Swipha), a leading pharmaceutical company in Nigeria.
Micro Labs Limited officially disclosed the acquisition to Pharmanews on Monday, noting that it retains all the existing staff of Swipha.
Micro Labs Limited (Micro Labs), India is a fully integrated pharmaceutical company primarily engaged in the manufacturing and marketing of branded generic formulations in India and emerging markets. The company specialises in manufacturing of high-quality, affordable generic medicines across a diverse range of therapeutic areas with several formulations listed on WHO Pre-qualification list including but not limited to Anti-Malaria.
According to the Managing Director of the company in Nigeria, Mr Hemant Sharma, and now Chairman of Swipha, Micro Labs’ portfolio includes cardiology, diabetology, pain management, dermatology, ophthalmology, veterinary, neurology.
With its headquarters in Bangalore, Karnataka, India, Micro Labs has a strategic network of 14 formulation plants, including an injectable unit and a bulk drug facility. The company has established international offices in key locations such as the United States, the United Kingdom, Germany, Australia, and Nigeria, with representative offices in emerging markets.
In Nigeria, the pharma company operates through Micro Nova Pharmaceutical Ind. Limited, with operations spanning over a decade in the Nigeria Pharmaceutical Industry space and has risen as market leader in specialised therapeutic segments.
Swipha on the other hand is a leading pharmaceutical company incorporated in 1976 dedicated to providing high-quality, affordable medicines to improve healthcare outcomes in Nigeria and Africa. Swipha is engaged in manufacturing, marketing, and distribution of high quality, affordable, branded generics, and INN. The portfolio includes therapeutic classes of central nervous system, anti-malaria, anti-infectives, cardiovascular system, and anti-diabetic.
Swipha is also first in Nigeria, West and Central Africa to attain WHO Pre-qualification for Zinc (Anti-Diarrhea) and Sulfadoxine, Pyrimethamine (Anti-Malaria) drugs.
While speaking on the benefit of the acquisition, Mr Sharma said “the acquisition will create significant value by consolidating both companies’ portfolios and its WHO journey with the aim of providing affordable, quality medicines to the people of Nigeria and Africa and as well expand the range of antimalaria, anti-infectives and cardio metabolism among others.
Sharma said “the acquisition will provide more comprehensive treatment options. Swipha’s distribution network, CRM, will improve supply chain efficiency, while its WHO-approved plant will enable Micro Labs to support manufacturing and export products to neighbouring countries.
“With Micro Labs presence across the entire pharmaceutical value chain – Research and Development (“R&D”), Active Pharmaceutical Ingredients (“APIs”), Finished Formulations, the synergies that will reduce costs. Both companies are known for their quality and business acumen, making this acquisition a strategic move to leverage their combined strengths for greater success.”
,){kind=link}